PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-0.68
Negative D/E while TRAW shows 0.00. Joel Greenblatt would look for hidden assets and restructuring catalysts.
-0.11
Net debt 1-2x EBITDA - Reasonable leverage that Peter Lynch might accept. Cross-check Current Ratio to verify short-term liquidity remains strong.
-6.94
Both companies show negative coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
0.01
Current ratio of 0.01 while TRAW has zero ratio. Bruce Berkowitz would examine if our working capital management provides advantages.
No Data
No Data available this quarter, please select a different quarter.